within Pharmacolibrary.Drugs.ATC.V;

model V08CA10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00016,
    k12             = 1.1,
    k21             = 1.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadoxetic acid (also known as gadoxetate disodium) is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI), particularly for hepatic (liver) imaging to detect and characterize focal liver lesions. It is approved for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Schwope, RB, et al., &amp; Margolis, DJ (2015). Gadoxetic acid: pearls and pitfalls. <i>Abdominal imaging</i> 40(6) 2012–2029. DOI:<a href=\"https://doi.org/10.1007/s00261-015-0354-7\">10.1007/s00261-015-0354-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25613332/\">https://pubmed.ncbi.nlm.nih.gov/25613332</a></p></li><li><p>Theilig, D, et al., &amp; Geisel, D (2019). Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. <i>Abdominal radiology (New York)</i> 44(8) 2759–2768. DOI:<a href=\"https://doi.org/10.1007/s00261-019-02036-w\">10.1007/s00261-019-02036-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31025071/\">https://pubmed.ncbi.nlm.nih.gov/31025071</a></p></li><li><p>Chen, YW, et al., &amp; Chou, CP (2014). Gadoxetic acid-enhanced MRI and sonoelastography: non-invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with Sho-Saiko-To. <i>PloS one</i> 9(12) e114756–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0114756\">10.1371/journal.pone.0114756</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25490034/\">https://pubmed.ncbi.nlm.nih.gov/25490034</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA10;
